4/18/2014 6:37:24 AM
Molecular Templates, Inc., a biopharmaceutical company focused on the discovery and development of a new class of biologic therapies announced today that it presented preclinical data in two poster presentations at the 105th annual meeting of the American Association for Cancer Research (AACR) in San Diego, CA from April 5th – 9th, 2014. In a presentation, entitled “CD20-specific Engineered Toxin Body Demonstrates Direct Cell Kill Of Multiple B-cell Non-Hodgkin‘s Lymphoma Types” (Abstract 647), the company reported on the development of MT-3724 that specifically targets the destruction of malignant cells expressing the CD20 receptor through a unique mechanism of cell kill.
Help employers find you! Check out all the jobs and post your resume.
comments powered by